These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 37100086)
1. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. Jo J; Diaz M; Horbinski C; Mackman N; Bagley S; Broekman M; Rak J; Perry J; Pabinger I; Key NS; Schiff D Neuro Oncol; 2023 Aug; 25(8):1381-1394. PubMed ID: 37100086 [TBL] [Abstract][Full Text] [Related]
2. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk? Jo J; Donahue J; Sarai G; Petroni G; Schiff D Neuro Oncol; 2022 Mar; 24(3):455-464. PubMed ID: 34383073 [TBL] [Abstract][Full Text] [Related]
3. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study. Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405 [TBL] [Abstract][Full Text] [Related]
4. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657 [TBL] [Abstract][Full Text] [Related]
5. Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients. Diaz M; Jo J Curr Oncol Rep; 2022 Apr; 24(4):493-500. PubMed ID: 35179708 [TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498 [TBL] [Abstract][Full Text] [Related]
8. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M; Porreca E; Otten HM; Rutjes AW Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319 [TBL] [Abstract][Full Text] [Related]
10. Chemoprophylaxis for venous thromboembolism in pelvic and/or acetabular fractures: A systematic review. Shu HT; Yu AT; Lim PK; Scolaro JA; Shafiq B Injury; 2022 Apr; 53(4):1449-1454. PubMed ID: 35148902 [TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism in cancer patients. Deng A; Galanis T; Graham MG Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915 [TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma. Dubinski D; Won SY; Voss M; Keil F; Miesbach W; Behmanesh B; Dosch M; Baumgarten P; Bernstock JD; Seifert V; Freiman TM; Gessler F Neurosurg Rev; 2022 Feb; 45(1):451-457. PubMed ID: 33900495 [TBL] [Abstract][Full Text] [Related]
13. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies. Swartz AW; Drappatz J Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555 [TBL] [Abstract][Full Text] [Related]
14. The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study. Fluss R; Kobets AJ; Inocencio JF; Hamad M; Feigen C; Altschul DJ; Lasala P Clin Neurol Neurosurg; 2021 Feb; 201():106460. PubMed ID: 33444944 [TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma. Dasgupta P; Rousseau JF J Neurooncol; 2024 Feb; 166(3):569-574. PubMed ID: 38286976 [TBL] [Abstract][Full Text] [Related]
16. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. Carney BJ; Uhlmann EJ; Puligandla M; Mantia C; Weber GM; Neuberg DS; Zwicker JI J Thromb Haemost; 2019 Jan; 17(1):72-76. PubMed ID: 30450803 [TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). Pernod G; Joly M; Sonnet B J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939 [TBL] [Abstract][Full Text] [Related]
18. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Forster R; Stewart M Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384 [TBL] [Abstract][Full Text] [Related]
19. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194 [TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M; Porreca E; Ferrante N; Otten HM; Cuccurullo F; Rutjes AW Cochrane Database Syst Rev; 2012 Feb; (2):CD008500. PubMed ID: 22336844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]